Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04833114
Title Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (Pola-R-ICE)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors GWT-TUD GmbH

B-cell lymphoma

primary mediastinal B-cell lymphoma

diffuse large B-cell lymphoma


Carboplatin + Etoposide + Ifosfamide + Rituximab

Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab

Age Groups: senior | adult
Covered Countries ESP | DEU | AUT

No variant requirements are available.